Dysregulated ether lipid metabolism is an important hallmark of cancer cells. Previous studies have reported that lowering ether lipid levels by genetic ablation of the ether lipid-generating enzyme alkyl-glycerone phosphate synthase (AGPS) lowers key structural and oncogenic ether lipid levels and alters fatty acid, glycerophospholipid, and eicosanoid metabolism to impair cancer pathogenicity, indicating that AGPS may be a potential therapeutic target for cancer. In this study, we have performed a small-molecule screen to identify candidate AGPS inhibitors. We have identified several lead AGPS inhibitors and have structurally characterized their interactions with the enzyme and show that these inhibitors bind to distinct portions of the active site. We further show that the lead AGPS inhibitor 1a selectively lowers ether lipid levels in several types of human cancer cells and impairs their cellular survival and migration. We provide here the first report of in situ-active pharmacological tools for inhibiting AGPS, which may provide chemical scaffolds for future AGPS inhibitor development for cancer therapy.

Discovery of inhibitors for the ether lipid-generating enzyme AGPS as anti-cancer agents / Piano, Valentina; Benjamin, Daniel I.; Valente, Sergio; Nenci, Simone; Marrocco, Biagina; Mai, Antonello; Aliverti, Alessandro; Nomura, Daniel K; Mattevi, Andrea. - In: ACS CHEMICAL BIOLOGY. - ISSN 1554-8929. - 10:11(2015), pp. 2589-2597. [10.1021/acschembio.5b00466]

Discovery of inhibitors for the ether lipid-generating enzyme AGPS as anti-cancer agents

VALENTE, Sergio;MARROCCO, BIAGINA;MAI, Antonello;
2015

Abstract

Dysregulated ether lipid metabolism is an important hallmark of cancer cells. Previous studies have reported that lowering ether lipid levels by genetic ablation of the ether lipid-generating enzyme alkyl-glycerone phosphate synthase (AGPS) lowers key structural and oncogenic ether lipid levels and alters fatty acid, glycerophospholipid, and eicosanoid metabolism to impair cancer pathogenicity, indicating that AGPS may be a potential therapeutic target for cancer. In this study, we have performed a small-molecule screen to identify candidate AGPS inhibitors. We have identified several lead AGPS inhibitors and have structurally characterized their interactions with the enzyme and show that these inhibitors bind to distinct portions of the active site. We further show that the lead AGPS inhibitor 1a selectively lowers ether lipid levels in several types of human cancer cells and impairs their cellular survival and migration. We provide here the first report of in situ-active pharmacological tools for inhibiting AGPS, which may provide chemical scaffolds for future AGPS inhibitor development for cancer therapy.
2015
biochemistry; molecular medicine; guinea-pig liver; dihydroxyacetone phosphate; cancer pathogenicity; alkyl; binding; biosynthesis; metabolism; antimycin; stability; glycerol
01 Pubblicazione su rivista::01a Articolo in rivista
Discovery of inhibitors for the ether lipid-generating enzyme AGPS as anti-cancer agents / Piano, Valentina; Benjamin, Daniel I.; Valente, Sergio; Nenci, Simone; Marrocco, Biagina; Mai, Antonello; Aliverti, Alessandro; Nomura, Daniel K; Mattevi, Andrea. - In: ACS CHEMICAL BIOLOGY. - ISSN 1554-8929. - 10:11(2015), pp. 2589-2597. [10.1021/acschembio.5b00466]
File allegati a questo prodotto
File Dimensione Formato  
Piano_Discovery_2015.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 466.72 kB
Formato Adobe PDF
466.72 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/856754
Citazioni
  • ???jsp.display-item.citation.pmc??? 28
  • Scopus 48
  • ???jsp.display-item.citation.isi??? 48
social impact